Beijing Business Daily (Reporter Ding Ning) On the evening of March 7, Xintian Pharmaceutical (002873) announced that it intends to purchase 85 Huilun Pharmaceutical held by 88 shareholders of Shanghai Huilun Pharmaceutical, including Dong Dalun, Dong Zhu and Hainan Qianyao, by issuing shares12% equity.
According to the data, Huilun Pharmaceutical's main business is the research and development, production and sales of small molecule chemical drugs, and is committed to innovation and development in the fields of immune inflammation, anti-tumor, cardiovascular and cerebrovascular, ** and other diseases. Xintian Pharmaceutical said that after the completion of this transaction, the company will further extend its industrial layout to cutting-edge pharmaceutical fields such as small molecule chemical drugs, form an industrial pattern of "traditional Chinese medicine and chemical medicine", realize the rich integration of product structure, further expansion of the first field and the upgrading of the future innovative drug pipeline, and rely on the integration with the underlying assets to enhance the company's product research and development capabilities, market competitiveness, sustainable development capabilities and anti-risk capabilities, etc., and accelerate the creation of a leading comprehensive pharmaceutical enterprise.
In addition, Xintian Pharmaceutical said that after the company's application to the Shenzhen Stock Exchange, the company's ** and convertible corporate bonds resumed trading since the market opened on March 8, and the convertible corporate bonds resumed their conversion on the same day.